challenge: What is a key characteristic of basimglurant, as demonstrated by preclinical research trials?
  
  A. High specificity for the dopamine receptor D2
  B. Low specificity for the glutamate receptor mGlu5
  C. High specificity for the glutamate receptor mGlu5
  D. Low level of safety due to non-specific binding
  Answer: 